<DOC>
	<DOCNO>NCT02077257</DOCNO>
	<brief_summary>This 12-week , randomize , open-label , ,multicenter , Phase IV study explore LDL-C lower efficacy Rosuvastatin 20 mg/d compare 10 mg/day Chinese ACS patients.The Randomized Treatment Period precede 24hours Screening Period . The study flow chart ( Figure 1 ) depict 2 period comprise study . These period describe follow : 1 . Screening Period ( Day -1 Day 1 ) This period consist Visits 1 2 . Subjects enter Screening Period require meet inclusion criterion . All subject instruct follow current TLC ( therapeutic lifestyle change ) dietary guideline duration trial . 2 . 12-week Randomized Treatment Period ( Day 1 Week 12 ) This period consist Visits 2 , 3 , 4 , 5 . Eligible subject randomize Visit 2 treatment group : Rosuvastatin 20 mg orRosuvastatin10 mg . Treatment administer daily 12 week . A total 450valid subject Rosuvastatin arm require , order test hypothesis superiority comparison LDL-C level Rosuvastatin20 mg Rosuvastatin10 mg ( see Section 6.1 detail ) . The Study visit schedule ( Table 2 ) indicate number timing plan visit . The visit schedule must within time window . At final visit , responsibility investigator ensure subject offer select appropriate type lipid-lowering therapy . Scheduled Visit3,4,5 visit window ±2 day . Subjects attend clinic visit without fast ( least 12 hour ) ask return within 2 day another clinic visit fast least 12 hour .</brief_summary>
	<brief_title>LDL-C Lowering Efficacy Safety Rosuvastatin 20 mg/Day to10 mg/Day Chinese ACS ( Acute Coronary Syndrome ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1880 year old male nonchildbearing period female . Clinical diagnose acute coronary syndrome include NSTEACS , MI STEMI . Patients STEMI ( ( ST segment elevation myocardial infarction ) NSTEMI ( nonST segment elevation myocardial infarction ) recruit within 48 hour symptom onset . The LDLC≥70mg/dL one week randomization . The TG &lt; 500mg/dL one week randomization . No cholesterollowering drug ( include lipid lower dietary supplement , antioxidant , food additive ) 4 week randomization . Sign ICF ( inform consent form ) Acute pulmonary edema , severe congestive heart failure , acute moderate mitral regurgitation , acute ventricular septal perforation , severe arrhythmia ( ventricular fibrillation , sustain ventricular tachycardia , complete heart block ) , sepsis , acute pericarditis , evidence systemic pulmonary embolus within precede 4 week . Coronary artery bypass graft within precede 3 month ; percutaneous coronary intervention within precede 6 month . A history hypersensitivity statins severe complication . childbearing woman hypothyroidism , active liver disease dysfunction include agnogenic serum transaminase sustain elevation high 3 time ULN ( upper limit normal ) severe anemia ( hemoglobin , hematocrit &lt; 28 % ) , Patients myopathy serum creatine kinase &gt; 3 time upper limit normal cause myocardial injury . A history psychiatric disorder A history jejunoileal bypass gastric bypass surgery Currently take steroid therapy Currently take phenytoin sodium , phenobarbital , carbamazepine ( may primary efficacy endpoint ) Diagnosed malignant within 5 year Severe renal function damage ( creatinine clearance rate &lt; 30 ml/min ) Concurrent use ciclosporin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>